MBio Diagnostics, Inc. Will Present at Biotech Showcase in San Francisco, Monday January 7, 2013
(firmenpresse) - BOULDER, CO -- (Marketwire) -- 01/03/13 -- MBio Diagnostics, Inc., a diagnostics company focused on enabling better healthcare decisions through immediate multi-disease diagnostics, today announced that Michael J. Lochhead, Ph.D., Vice President of MBio Diagnostics, will present a company overview at the Biotech Showcase, on Monday, January 7 at 2:30 p.m. PST at the Parc 55 Hotel in San Francisco, CA. The presentation will focus on MBio's near-term plans to commercialize the first in a pipeline of diagnostic products on a single platform developed to deliver comprehensive testing of multiple diseases from a single sample.
MBio Diagnostics, Inc. () is a privately held clinical diagnostics and life sciences technology company based in Boulder, CO. MBio is developing a suite of simple, multiplexed diagnostic tests using its proprietary LightDeck™ technology. Initial product development focuses on high impact infectious diseases, including HIV, hepatitis, and influenza. The company's product development is aimed at decentralized testing, from the clinic to the home.
For more information visit MBio at or contact:
Michael Seely
MBio Diagnostics, Inc.
Phone: 303-952-2830
Fax: 303-951-1529
E-mail:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 03.01.2013 - 16:00 Uhr
Sprache: Deutsch
News-ID 1184141
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
BOULDER, CO
Phone:
Kategorie:
Venture Capital
Anmerkungen:
Diese Pressemitteilung wurde bisher 146 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MBio Diagnostics, Inc. Will Present at Biotech Showcase in San Francisco, Monday January 7, 2013
"
steht unter der journalistisch-redaktionellen Verantwortung von
MBio Diagnostics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
